Dosage questions surround Novo Nordisk Next-Gen Perous of Weight Loss

Chicago – The injection of new generation obesity of NOVO Nordisk targeting amyline hormone has shown substantial weight loss in an early study, but similar efficiency between different doses and high levels of side effects raise questions about the Novo dose in the future.

In phase 1/2, the study testing the medication, called Amycretine, patients on the highest dose of 60 mg lost an average of 24.3% of their weight at 36 weeks, while those on Landbo lost 1.1%, according to the results published Friday in Lancet which will also be presented at the American Diabetes Association conference. These results suggest that Amycretine could be more effective than other drugs on the market.

In another part of the study, testing doses of 20 mg, 5 mg and 1.25 mg of amycritine, patients also underwent substantial weight loss, but with overlapping weight loss curves. The result is unusual because researchers generally expect a dose-dependent effect, where patients at higher doses lose more weight more quickly.